Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure

Author:

Nick Heidi J.,Zeitlin Pamela L.,Yadav Sangya,Bratcher Preston E.

Abstract

AbstractQuantitation of CFTR function in vitro is commonly performed by acutely stimulating then inhibiting ion transport through CFTR and measuring the resulting changes in transepithelial voltage (Vte) and current (ISC). While this technique is suitable for measuring the maximum functional capacity of CFTR, it may not provide an accurate estimate of in vivo CFTR activity. To test if CFTR-mediated ion transport could be measured in the absence of acute CFTR stimulation, primary airway epithelia were analyzed in an Ussing chamber with treatment of amiloride followed by CFTR(inh)-172 without acute activation of CFTR. Non-CF epithelia demonstrated a decrease in Vte and ISC following exposure to CFTR(inh)-172 and in the absence of forskolin/IBMX (F/I); this decrease is interpreted as a measure of spontaneous CFTR activity present in these epithelia. In F508del/F508del CFTR epithelia, F/I-induced changes in Vte and ISC were ~ fourfold increased after treatment with VX-809/VX-770, while the magnitude of spontaneous CFTR activities were only ~ 1.6-fold increased after VX-809/VX-770 treatment. Method-dependent discrepancies in the responses of other CF epithelia to modulator treatments were observed. These results serve as a proof of concept for the analysis of CFTR modulator responses in vitro in the absence of acute CFTR activation. Future studies will determine the usefulness of this approach in the development of novel CFTR modulator therapies.

Funder

Department of Pediatrics at National Jewish Health

Cystic Fibrosis Foundation

Gilead Sciences Research Scholars Program in Cystic Fibrosis

Eugene F. and Easton M. Crawford Charitable Lead Unitrust

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference36 articles.

1. Clancy, J. P. et al. CFTR modulator theratyping: Current status, gaps and future directions. J. Cyst. Fibros. 18, 22–34. https://doi.org/10.1016/j.jcf.2018.05.004 (2019).

2. U.S. Food and Drug Administration. FDA Expands Approved Use of Kalydeco to Treat Additional Mutations of Cystic Fibrosis: Laboratory Evidence Used to Support Efficacy. https://www.fda.gov/news-events/press-announcements/fda-expands-approved-use-kalydeco-treat-additional-mutations-cystic-fibrosis (2017).

3. Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 11, 237–245. https://doi.org/10.1016/j.jcf.2011.12.005 (2012).

4. Guimbellot, J. et al. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J. Cyst. Fibros. 18, 102–109. https://doi.org/10.1016/j.jcf.2018.04.004 (2019).

5. Vertex Pharamceuticals. KALYDECO® Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203188s028,207925s007lbl.pdf (2018).

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro;Journal of Cystic Fibrosis;2022-07

2. Assays of CFTR Function In Vitro, Ex Vivo and In Vivo;International Journal of Molecular Sciences;2022-01-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3